SPDS Advisory Panel 12-02-2014

I.

WELCOME AND INTRODUCTIONS Dawn Frazier welcomed Advisory Panel members and initiated introductions. Darryl Sullivan discussed with the panel, the goal of the meeting. The goal of the meeting is to identify and/or recommend the next four (4) priority dietary supplement ingredients.

II.

DISCUSSION ON PRIORITIZING NEXT SET OF INGREDIENTS

A. INGREDIENT RANKING FEEDBACK Previously, the Advisory Panel members revised the ranking weight of the Ingredient Ranking Chart to assist in establishing a method for prioritizing the next set of ingredients. Based upon the feedback received, Table 1 represents the Ingredient Ranking Charts for the top 10 priority ingredients as received by American Herbal Products Associations (AHPA), Council for Responsible Nutrition (CRN), and Herbalife. Each group solicited feedback from their members and within their organizations. AHPA based its rankings on the average input of AHPA members. CRN ranked their ingredients on a scale from 5-1 with indications for high and medium priorities. Herbalife ranked their ingredients based on the need for Standard Method Performance Requirements (SMPRs) and/or single laboratory validations indicated with either higher or lower priority levels. Please refer to Table 1. Table 1

AHPA

CRN

Herbalife

Ashwagandha (Withania somnifera)

Lutein and its esters

1 2

Aloe

Ginseng

Vitamin D

Angelica/ Dong Quai

Folin C; two methods: determination of total polyphenols and antioxidant potential

Grape Seed Extract‐ Proanthocyanidines (Polyphenols)

3 4 5 6 7

Ashwagandha (Withania somnifera)

Turmeric Ginger Lutein Bacopa Cinnamon

Pomegranate Olive Leaf Milk Thistle

Astragalus

Bacopa

Boswellia

Phytosterols & (Phytosterol esters) Cinnamon

Folin C; two methods: determination of total polyphenols and antioxidant potential

8 9

Eleuthero Root

Vitamin B6 Boswellia

Cranberry Echinacea

Ganoderma lucidum

10

Goji (wolfberry or Lycium barbarum)

B. IDENTIFICATION OF NEXT FOUR (4) INGREDIENTS) Sullivan led the Advisory Panel discussion on identifying and ranking the next four (4) priority ingredients. There were discussions on safety concerns, USP monographs, and which ingredients had previous work done (i.e. single laboratory validation studies, expert review panels, etc.).